Patent classifications
A61P7/08
UTI FUSION PROTEINS
The present invention provides UTI fusion proteins, DNA sequences for producing the same, and pharmaceutical compositions and methods of using the same.
Engineered heme-binding compositions and uses thereof
Described herein are heme-binding compositions and methods relating to their use, for example methods of treatment of sepsis and rhabdomyolysis.
Spray-Dried Blood Products and Methods of Making Same
The present invention is directed to a method of preparing dehydrated blood products, comprising the steps of: (a) providing a hydrated blood product; (b) spray-drying the hydrated blood product to produce a dehydrated blood product, as well as dehydrated blood products made by the method. The present invention is directed to a method of treating a patient suffering from a blood-related disorder, comprising the steps of: (a) rehydrating a therapeutic amount of the dehydrated blood products to produce a rehydrated therapeutic composition; and (b) administering the rehydrated therapeutic composition to the patient. The present invention is directed to a bandage or surgical aid comprising the dehydrated blood products described above.
Compositions and Methods for Treating Hemorrhagic Shock
Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carried (HBOC) and blood plasma. Related methods to prepare the pharmaceutical preparations are also provided. Furthermore, methods to prevent or treat hemorrhagic shock are provided.
Compositions and Methods for Treating Hemorrhagic Shock
Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carried (HBOC) and blood plasma. Related methods to prepare the pharmaceutical preparations are also provided. Furthermore, methods to prevent or treat hemorrhagic shock are provided.
Compositions of fluorocarbon nanoemulsion, and methods of preparation and use thereof
The invention provides novel compositions of fluorocarbon nanoemulsions comprising one or more of fluorosurfactants and phospholipids, and methods of preparation and use thereof for enhanced oxygen delivery.
PERITONEAL DIALYSIS SOLUTION
In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.
PERITONEAL DIALYSIS SOLUTION
In alternative embodiments, provided are solutions for peritoneal dialysis for use for maintaining or restoring the removal of small solutes and fluids in subjects with end-stage renal disease and/or congestive heart failure. In alternative embodiments, such solutions comprise carnitine, xylitol and at least one of glucose, glycerol and polydextrin.
OXYGENATION MEDIA FOR EX-VIVO PRESERVATION OF ORGANS AND TISSUES
Oxygenation constituents and finished oxygenation media, as well as methods of making oxygenation constituents and finished oxygenation media are provided. The oxygenation constituents comprise a hemoglobin preparation, and a red blood cell preparation. The oxygenation constituents comprise from about 10% to about 99% by weight hemoglobin of the hemoglobin preparation and the balance by weight hemoglobin of the oxygenation constituents comprise a red blood cell preparation. The finished oxygenation media comprise the oxygenation constituents and one or more other ingredients such as a diluent, or excipient. The finished oxygenation media can be used to ex-vivo preserve organs or tissue.
AGENT FOR SUPPRESSING ALCOHOL SICKNESS OR HANGOVER DUE TO ALCOHOLIC BEVERAGE INGESTION
The present invention provides a food composition or pharmaceutical composition which includes, as an active ingredient, citric acid or a salt thereof. Ingestion or administration of the food composition or pharmaceutical composition leads to suppression of alcohol sickness or hangover due to alcoholic beverage ingestion; suppression of an increase in blood alcohol level, an increase in blood acetaldehyde level, or an increase in blood acetic acid level due to alcoholic beverage ingestion; suppression of a decrease in blood pyruvic acid level due to alcoholic beverage ingestion; suppression of an abnormal blood lactic acid/pyruvic acid ratio due to alcoholic beverage ingestion; suppression of an increase in blood alcohol level immediately after alcohol ingestion; suppression of alcohol absorption; promotion of alcohol metabolism; or an increase in blood ornithine level, blood serotonin level, blood taurine level, blood cystine level, or blood nicotine amide level.